ReviewClinical science (London, England : 1979)2026
Sex-dependent differences in mitochondrial protein acetylation in metabolic condition, oxidative stress, vascular dysfunction, hypertension, and cardiovascular disease.
Review in Clinical science (London, England : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
One half of adults have hypertension, which is a major risk factor for stroke, myocardial infarction, heart failure, and vascular dementia. There is an urgent need for new therapies, particularly for women with hypertension. Hypertension affects women in all phases of life; however, the hypertension rate increases in women much more steeply, and hypertensive vascular and kidney damage is significantly higher in women. Despite great burden, only 1 in 4 patients have their blood pressure under control. Hypertension accounts for 1 in 5 deaths among American women, posing a greater burden for women than men. Meanwhile, female-specific aspects of hypertension are poorly understood, and women or female-specific risk factors are understudied in basic, clinical, and population research and hypertension guidelines. Understanding these mechanisms can help to develop new therapies. Endothelial dysfunction has a profound prognostic implication predicting adverse cardiovascular events. We suggest that female antihypertensive protection is critically dependent on mitochondrial pathways preserving endothelial function. Metabolic disorders and oxidative stress contribute to the pathogenesis of these conditions, which are linked to mitochondrial dysfunction. Proteomic studies showed higher expression of mitochondrial fatty acid oxidation and antioxidant enzymes in females, and oxidative damage is lower in females compared with males. Meanwhile, the actual activity of these mitochondrial metabolic and antioxidant enzymes is regulated by acetylation, but sex-specific differences in mitochondrial acetylation in vascular disease have not been studied. In the present review, we will discuss potential sex differences in mitochondrial protein acetylation and its implications in metabolic conditions, oxidative stress, vascular dysfunction, hypertension, and cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.